AI assistant
Sending…
LENZ Therapeutics, Inc. — Director's Dealing 2021
Jun 29, 2021
32045_dirs_2021-06-28_320979b1-a122-4ed7-8a36-9822a5e17da9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Graphite Bio, Inc. (GRPH)
CIK: 0001815776
Period of Report: 2021-06-24
Reporting Person: Carlo Rizzuto (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-24 | Stock Option (right to buy) | $17.00 | A | 40000 | Acquired | 2031-06-23 | Common Stock (40000) | Direct |
Footnotes
F1: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of June 24, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.
More from LENZ Therapeutics, Inc.
Annual Report
2026
Apr 28
Director's Dealing
2026
Mar 30
Director's Dealing
2026
Mar 30
Director's Dealing
2026
Mar 30
Regulatory Filings
2026
Mar 24
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 5
Major Shareholding Notification
2026
Jan 21
Regulatory Filings
2026
Jan 7
Director's Dealing
2026
Jan 6